Cohort 1 comprised 27 NSCLC patients (16 in the DCB group and 11 in the NDB group) treated with PD-1 inhibitor monotherapy between May 2021 and April 2022. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.